Compare EVI & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVI | ABOS |
|---|---|---|
| Founded | 1959 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 204.6M | 197.9M |
| IPO Year | 1995 | 2021 |
| Metric | EVI | ABOS |
|---|---|---|
| Price | $17.89 | $2.64 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $35.00 | $8.00 |
| AVG Volume (30 Days) | 43.4K | ★ 304.6K |
| Earning Date | 05-15-2026 | 05-12-2026 |
| Dividend Yield | ★ 1.81% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.48 | N/A |
| Revenue | ★ $389,830,000.00 | N/A |
| Revenue This Year | $15.53 | N/A |
| Revenue Next Year | $3.83 | N/A |
| P/E Ratio | $36.82 | ★ N/A |
| Revenue Growth | ★ 10.26 | N/A |
| 52 Week Low | $12.75 | $1.22 |
| 52 Week High | $34.75 | $3.60 |
| Indicator | EVI | ABOS |
|---|---|---|
| Relative Strength Index (RSI) | 71.62 | 43.31 |
| Support Level | $16.41 | $2.13 |
| Resistance Level | $21.36 | $2.77 |
| Average True Range (ATR) | 1.09 | 0.20 |
| MACD | 0.41 | -0.07 |
| Stochastic Oscillator | 93.57 | 14.06 |
EVI Industries Inc is a value-added distributor and service provider in the commercial laundry industry. It sells and leases commercial laundry equipment, specializing in washing, drying, finishing, material handling, water heating, power generation, and water reuse applications. The company supports its equipment offerings with installation, maintenance, and repair services through a large network of trained technicians. It serves a wide range of customers, including commercial, industrial, institutional, government, and retail sectors. Geographically, the company serves various countries including United States, Canada, the Caribbean, and Latin America.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.